Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Study Identifier
Pro2
CT.gov Identifier
NCT00716742
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Glaucoma - Open Angle
  • Ocular Hypertension
    • Study Drug
  • bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%
    • Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * A diagnosis of Primary Open-Angle Glaucoma or Ocular Hypertension newly diagnosed OR presenting with insufficiently controlled IOP on current medication (in the opinion of the treating physician) * Patient is having both eyes treated
    Exclusion Criteria:
    * Contraindications per product labelling will apply. * Patients with any ophthalmic co-morbidity with an influence on visual field deterioration or optic nerve head damage.

    Protocol Summary

    To investigate the effectiveness of the newer IOP-lowering therapies, as prescribed in normal clinical practice, in larger patient numbers. Patients will be assessed at baseline, at each follow-up visit (follow-up visits are variable as per physician discretion) and at final follow-up visit.

    Study Locations

    Location
    Status
    Location
    Murfreesboro, Tennessee, United States
    Status
    Not applicable